osama Gheith

Dr. osama Gheith

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2015
Verified
Journal Article
Open access
OGosama Gheith
osama Gheith
NFNashwa Farouk
Nashwa Farouk
NNNarayanan Nampoory
Narayanan Nampoory
MHMedhat A Halim
Medhat A Halim
TATorki Al-Otaibi
Torki Al-Otaibi
Diabetic kidney disease – which is defined by elevated urine albumin excretion or reduced glomerular filtration rate (GFR) or both – is a serious complication that occurs in 20% to 40% of all diabetics. In this review we try to highlight the prevalence of diabetic nephropathy which is not uncommon complication of diabetes all over the world. The prevalence of diabetes worldwide has extended epidemic magnitudes and is expected to affect more than 350 million people by the year 2035. There is marked racial/ethnic besides international difference in the epidemiology of diabetic kidney disease which could be explained by the differences in economic viability and governmental infrastructures. Approximately one-third of diabetic patients showed microalbuminuria after 15 years of disease duration and less than half develop real nephropathy. Diabetic kidney disease (DKD) is more frequent in African-Americans, Asian-Americans, and Native Americans. Progressive kidney disease is more frequent in Caucasians patients with type 1 than type 2 diabetes mellitus (DM), although its overall prevalence in the diabetic population is higher in patients with type 2 DM while this type of DM is more prevalent. Hyperglycemia is well known risk factor for in addition to other risk factors like male sex, obesity, hypertension, chronic inflammation, resistance to insulin, hypovitaminosis D, and dyslipidemia and some genetic loci and polymorphisms in specific genes. Management of its modifiable risk factors might help in reducing its incidence in the nearby future.

1 May 2004 in Transplantation
Verified
Journal Article
Closed access
AEAmgad E. El-Agroudy
Amgad E. El-Agroudy
EWEhab W. Wafa
Ehab W. Wafa
OGosama Gheith
osama Gheith
AEAhmed B. Shehab El-Dein
Ahmed B. Shehab El-Dein
MGMohamed A. Ghoneim
Mohamed A. Ghoneim
The present study aimed to evaluate the effect of weight gain after transplantation on patient and graft outcome. Patients receiving kidney transplants between April 1986 and April 2001 were divided according to their body mass index (BMI) at 6 months after transplantation into group I, BMI less than 25 (normal weight); group II, BMI greater than or equal to 25 and less than 30 (overweight); and group III, BMI greater than or equal to 30 (obese) after exclusion of pediatric patients (aged ≤18 years), second transplant recipients, those with a history of cardiovascular disease, and those with a BMI less than 25 and greater than 18.5 kg/m2. Six hundred fifty kidney transplant recipients were selected for this retrospective study. There was a statistically significant increase in the incidence of posttransplant hypertension, diabetes mellitus, and ischemic heart disease in the obese group. The incidence and frequency of acute rejection episodes were similar in the three groups. A trend toward decreased graft and patient survival, which reached significance at 5 years and 10 years, was observed in the obese group. BMI has a strong association with outcomes after renal transplantation independent of most of the known risk factors for patient and graft survival.

1 January 2010 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
MFMohamed Ashraf Fouda
Mohamed Ashraf Fouda
OGosama Gheith
osama Gheith
ARAyman Refaie
Ayman Refaie
MEMohamed El-Saeed
Mohamed El-Saeed
ABAdel Bakr
Adel Bakr
MSMohamed Sobh
Mohamed Sobh
Kimura disease (KD) is a chronic inflammatory disorder with angiolymphatic proliferation, usually affecting young men of Asian race but is rare in other races. The etiology of KD is still unknown. It is often accompanied by nephrotic syndrome. Herein, we present an atypical manifestation of Kimura disease occurring in a Caucasian man with steroid-responsive early membranous glomerulonephritis. Kimura disease can present atypically in a middle-aged Caucasian man with secondary steroid-responsive nephrotic syndrome. Steroid, endoxan, and MMF can be used safely and successfully in such situation. The diagnosis of KD can be difficult and misleading, and patients with this disease are often evaluated using avoidable procedures by just not being aware of KD.

7 April 2021 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
AAAhmad Abbas
Ahmad Abbas
TATorki Al-Otaibi
Torki Al-Otaibi
OGosama Gheith
osama Gheith
ANAyman Maher Nagib
Ayman Maher Nagib
MFMahmoud M. Farid
Mahmoud M. Farid
MWMohammad Walaa
Mohammad Walaa
COVID-19,medical errors,sleep quality

15 July 2002 in Nephron
Verified
Journal Article
Closed access
PDF file
OGosama Gheith
osama Gheith
MSMohamed Abel-Kader Sobh
Mohamed Abel-Kader Sobh
KMKefaia El-Sayed Mohamed
Kefaia El-Sayed Mohamed
MEMahmoud Abdo El-Baz
Mahmoud Abdo El-Baz
FEFatma El-Husseini
Fatma El-Husseini
GAGalal Mohamed Amer
Galal Mohamed Amer
In this study 43 patients with idiopathic nephrotic syndrome were randomly distributed into 2 age- and sex-matched groups. The first group was given fluvastatin while the second was used as control. The cases in the 2 groups were evaluated clinically, biochemically (creatinine clearance, albumin, 24-hour proteinuria, and lipogram), neurologically, and histopathologically (examination of renal biopsies obtained basally and after 1 year of treatment with fluvastatin). In the fluvastatin-treated group but not in the control group, we observed a significant reduction in cholesterol, low-density lipoprotein, and triglyceride. Clinical and laboratory assessment showed satisfactory tolerance of the drug by the patients. Proteinuria, serum albumin and creatinine clearance values were significantly better in the statin-treated patients. There was no difference in glomerular sclerosis between the 2 groups while interstitial fibrosis and renal fat deposits were less in the statin-treated group. The reduction in renal fat deposits in the statin-treated group was highly significant, while that of interstitial fibrosis was not. We conclude that: (1) statin can be safely and effectively used in the treatment of dyslipidemia in patients with persistent idiopathic nephrotic syndrome; (2) control of dyslipidemia in nephrotic patients is associated with better control of proteinuria and creatinine clearance; (3) statin treatment may cause regression of renal fat deposits in patients with nephrotic syndrome, and (4) longer term studies are still required to study further possible beneficial effects on renal histology and disease progression.

26 March 2008 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
OGosama Gheith
osama Gheith
HSHussein Sheashaa
Hussein Sheashaa
MAMohamed Abdelsalam
Mohamed Abdelsalam
ZSZaki Shoeir
Zaki Shoeir
MSMohamed Sobh
Mohamed Sobh